MiRNA-29c regulates cell growth and invasion by targeting CDK6 in bladder cancer

American Journal of Translational Research

Volumn 7, Issue 8, 2015, Pages 1382-1389

  Zhao, Xin ^a   Li, Junliang ^a   Huang, Shengsong ^a   Wan, Xiaodong ^a   Luo, Huarong ^a   Wu, Denglong ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Bladder cancer; CDK6; MiR 29c; Proliferation

Indexed keywords

CYCLIN DEPENDENT KINASE 6; MICRORNA 29;

ARTICLE; BLADDER CANCER; CELL CYCLE ASSAY; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION ASSAY; COLONY FORMATION; CONTROLLED STUDY; FILTERS AND MEMBRANES; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUCIFERASE ASSAY; MTT ASSAY; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84941254389     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Parkin DM. The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl 2008; 218: 12-20.
2. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol 2009; 27: 289-293.
3. Crawford JM. The origins of bladder cancer. Lab Invest 2008; 88: 686-693.
4. Micheli A, Francisci S, Krogh V, Rossi AG, Crosignani P. Cancer prevalence in Italian cancer registry areas: the ITAPREVAL study. ITAPREVAL working group. Tumori 1999; 85: 309-369
5. Voutsinas GE, Stravopodis DJ. Molecular targeting and gene delivery in bladder cancer therapy. J Buon 2009; 14: S69-78.
6. Malmström PU, Loskog AS, Lindqvist CA, Mangsbo SM, Fransson M, Wanders A, Gårdmark T, Tötterman TH. AdCD40L immunogene therapy for bladder carcinoma the first phase I/IIa trial. Clin Cancer Res 2010; 16: 3279- 3287.
7. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr. Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287- 5312.
8. Bushati N and Cohen SM. microRNA functions. Annu Rev Cell Dev Biol 2007; 23: 175-205.
9. Ryan BM, Robles AI and Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010; 10: 389-402.
10. Xiang Y, Zhu ZQ, Han G, Ye X, Xu B, Peng Z, Ma Y, Yu Y, Lin H, Chen AP, Chen CD. JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. PNAS 2007; 104: 19226- 19231.
11. Mo W, Zhang J, Li X, Meng D, Gao Y, Yang S, Wan X, Zhou C, Guo F, Huang Y, Amente S, Avvedimento EV, Xie Y, Li Y. Identification of novel AR-targeted microRNAs mediating androgen signaling through critical pathways to regulate cell viability in prostate cancer. PLoS One 2013; 8: e56592.
12. Malumbres M, Barbacid M. Mammalian cyclindependent kinases. Trends Biochem Sci 2005; 30:630-641.
13. Lee KH, Lotterman C, Karikari C, Omura N, Feldmann G, Habbe N, Goggins MG, Mendell JT, Maitra A. Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology 2009; 9: 293-301.
14. Chilosi M, Doglioni C, Yan Z, Lestani M, Menestrina F, Sorio C, Benedetti A, Vinante F, Pizzolo G, Inghirami G. Differential expression of cyclin- dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia. Am J Pathol 1998; 152: 209-217.
15. Costello JF, Plass C, Arap W, Chapman VM, Held WA, Berger MS, Su Huang HJ, Cavenee WK. Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using twodimensional separation of genomic DNA. Cancer Res 1997; 57: 1250-1254.
16. Mendrzyk F, Radlwimmer B, Joos S, Kokocinski F, Benner A, Stange DE, Neben K, Fiegler H, Carter NP, Reifenberger G, Korshunov A, Lichter P. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol 2005; 23: 8853-8862.
17. Wang G, Zheng L, Yu Z, Liao G, Lu L, Xu R, Zhao Z, Chen G. Increased cyclin-dependent kinase 6 expression in bladder cancer. Oncol Lett 2012; 4: 43-46.
18. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
19. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, Schwind S, Pang J, Yu J, Muthusamy N, Havelange V, Volinia S, Blum W, Rush LJ, Perrotti D, Andreeff M, Bloomfield CD, Byrd JC, Chan K, Wu LC, Croce CM, Marcucci G. MicroRNA- 29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloidleukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 2009; 113: 6411-6418.
20. Santanam U, Zanesi N, Efanov A, Costinean S, Palamarchuk A, Hagan JP, Volinia S, Alder H, Rassenti L, Kipps T, Croce CM, Pekarsky Y. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci U S A 2010; 107: 12210-12215.
21. Sengupta S, den Boon JA, Chen IH, Newton MA, Stanhope SA, Cheng YJ, Chen CJ, Hildesheim A, Sugden B and Ahlquist P. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci U S A 2008; 105: 5874-5878.
22. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. MicroRNA gene expression deregulation in human breast cancer. Can Res 2005; 65: 7065-7070.
23. Wang H, Zhu Y, Zhao M, Wu C, Zhang P, Tang L, Zhang H, Chen X, Yang Y, Liu G. miRNA-29c suppresses lung cancer cell adhesion to extracellular matrix and metastasis by targeting integrin β1 and matrix metalloproteinase2 (MMP2). PLoS One 2013; 8: e70192.
24. Yang IP, Tsai HL, Huang CW, Huang MY, Hou MF, Juo SH, Wang JY. The functional significance of microRNA-29c in patients with colorectal cancer: a potential circulating biomarker for predicting early relapse. PLoS One 2013; 8: e66842.
25. Saito Y, Suzuki H, Imaeda H, Matsuzaki J, Hirata K, Tsugawa H, Hibino S, Kanai Y, Saito H, Hibi T. The tumor suppressor microRNA-29c is downregulated and restored by celecoxib in human gastric cancer cells. Int J Cancer 2013; 132: 1751-1760.
26. HJ Bae, JH Noh, JK Kim, JW Eun, KH Jung, MG Kim, YG Chang, Q Shen, Kim SJ, WS Park, JY Lee and SW Nam. MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma. Oncogene 2014; 33: 2557-2567.